scholarly journals Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer

2019 ◽  
Vol 13 (12) ◽  
Author(s):  
Ranjena Maloni ◽  
Luke T. Lavallée ◽  
Kristen McAlpine ◽  
Anil Kapoor ◽  
Frédéric Pouliot ◽  
...  
Keyword(s):  
Cancer Research ◽  
Kidney Cancer ◽  
Renal Mass ◽  
Consensus Statement ◽  
Research Network ◽  
Cancer Research Network ◽  
Renal Mass Biopsy

scholarly journals The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians

2017 ◽  
Vol 11 (12) ◽  
pp. 379-87 ◽  
Author(s):  
Jennifer Jones ◽  
Jaimin Bhatt ◽  
Jonathan Avery ◽  
Andreas Laupacis ◽  
Katherine Cowan ◽  
...  
Keyword(s):  
Cancer Research ◽  
Kidney Cancer ◽  
Priority Setting ◽  
Research Priorities ◽  
Research Network ◽  
Cancer Research Network ◽  
Research Priority ◽  
Funding Agencies ◽  
James Lind Alliance ◽  
Priority Setting Partnership

It is critically important to define disease-specific research priorities to better allocate limited resources. There is growing recognition of the value of involving patients and caregivers, as well as expert clinicians in this process. To our knowledge, this has not been done this way for kidney cancer. Using the transparent and inclusive process established by the James Lind Alliance, the Kidney Cancer Research Network of Canada (KCRNC) sponsored a collaborative consensus-based priority-setting partnership (PSP) to identify research priorities in the management of kidney cancer. The final result was identification of 10 research priorities for kidney cancer, which are discussed in the context of current initiatives and gaps in knowledge. This process provided a systematic and effective way to collaboratively establish research priorities with patients, caregivers, and clinicians, and provides a valuable resource for researchers and funding agencies.

scholarly journals Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021

2021 ◽  
Vol 15 (4) ◽  
pp. 84-97
Author(s):  
Christina Christina Canil ◽  
Anil Kapoor ◽  
Naveen S. Basappa ◽  
Georg Bjarnason ◽  
Dominick Bossé ◽  
...  
Keyword(s):  
Cancer Research ◽  
Kidney Cancer ◽  
Research Network ◽  
Cancer Research Network

scholarly journals Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019

2019 ◽  
Vol 13 (10) ◽  
pp. 343-54 ◽  
Author(s):  
Sebastien J. Hotte ◽  
Anil Kapoor ◽  
Naveen S. Basappa ◽  
Georg Bjarnason ◽  
Christina Canil ◽  
...  
Keyword(s):  
Cancer Research ◽  
Kidney Cancer ◽  
Research Network ◽  
Cancer Research Network

scholarly journals Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials

2018 ◽  
Vol 12 (6) ◽  
pp. 173-80 ◽  
Author(s):  
Pierre I. Karakiewicz ◽  
Emanuele Zaffuto ◽  
Anil Kapoor ◽  
Naveen S. Basappa ◽  
Georg A. Bjarnason ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cancer Research ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Review Process ◽  
Consensus Statement ◽  
Meta Analysis ◽  
Research Network ◽  
Cancer Research Network ◽  
One Year

Introduction: The Kidney Cancer Research Network of Canada (KCRNC) collaborated to prepare this consensus statement about the use of target agents as adjuvant therapy in patients with nonmetastatic renal cell carcinoma (nmRCC) after nephrectomy. We reviewed the published data and performed a meta-analysis of studies that focused on vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs).Methods: A systematic literature search identified seven trials on adjuvant target therapy in nmRCC. Three trials, the ASSURE, S-TRAC, and PROTECT, focused on VEGFR TKIs and represented the focus of the study, including a meta-analysis combining their data on disease-free survival (DFS) and overall survival (OS).Results: The ASSURE trial showed no DFS or OS benefit of TKIs over placebo after one year of adjuvant sorafenib or sunitinib. In contrast, the S-TRAC trial showed improved DFS after one year of adjuvant sunitinib using central review process, but not using investigator review process. No OS benefit was recorded in either study. Recently, the PROTECT trial also showed no DFS or OS benefit when one year of adjuvant pazopanib was compared to placebo. Meta-analyses of the pooled DFS and OS estimates from all three trials resulted in DFS and OS hazard ratios of 0.87 (95% confidence interval [CI] 0.73‒1.04) and 1.04 (95% CI 0.89‒1.22), respectively.Conclusions: Data from three available clinical trials of adjuvant VEGFR TKIs vs. placebo do not currently support the use of adjuvant TKI therapy as standard of care after nephrectomy for nmRCC. At this time, adjuvant TKI-based adjuvant therapy is not recommended for routine use after nephrectomy for high-risk nmRCC, but highly motivated patients may benefit from a discussion with their oncologist regarding the risks and benefits of adjuvant TKI.

scholarly journals PS1-23: Capitalizing on the HMO Cancer Research Network (CRN): The Optimal Setting to Conduct Studies of Rare Complex Diseases

2013 ◽  
Vol 11 (3) ◽  
pp. 128-128
Author(s):  
C. C. Johnson ◽  
C. Chao ◽  
L. Engel ◽  
H. Feigelson ◽  
J. Fortuny ◽  
...  
Keyword(s):  
Cancer Research ◽  
Complex Diseases ◽  
Research Network ◽  
Cancer Research Network ◽  
Optimal Setting

166: Searching for MARS-2: The North Trent Cancer Research Network Specialist Mesothelioma MDT screening experience

Lung Cancer ◽  
2017 ◽  
Vol 103 ◽  
pp. S76-S77
Author(s):  
S. Ajab ◽  
S.S.S. Begum ◽  
H. Stanley ◽  
S. Matthews ◽  
P.M. Fisher ◽  
...  
Keyword(s):  
Cancer Research ◽  
Research Network ◽  
Cancer Research Network ◽  
The North
Sign in / Sign up

Export Citation Format

Share Document